• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm

Article

Elzonris Product Image

ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)

Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle

  • First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting

Contraindications: None

Click here for more prescribing information

© 2023 MJH Life Sciences

All rights reserved.